3D128 is a next-generation off-the-shelf in vivo CAR-T gene therapy product developed by 3D Medicines, with its development primarily focused on hematological malignancies and autoimmune diseases.

It is poised to revolutionize the traditional gene therapy paradigm and address three core pain points: accessibility, safety, and high cost.

3D128 is underpinned by a differentiated, in-house developed delivery system.

tLNP enables specific delivery of GFP mRNA to resting T cells and NK cells in PBMCs. In the absence of cytokine stimulation, GFP protein expression persists for at least 7 days; while expression declines on day 11, it still exceeds expectations.

CD7-B051-tLNP achieves highly efficient transfection of T/NK cells in resting PBMCs.

3D Medicines tLNP Expression

mRNA Expression in Published Literature